Abstract: Imidazole Ketone Erastin (IKE) is a highly potent, improved analogue of the classic ferroptosis inducer erastin. By effectively inhibiting the system Xc- antiporter at low concentrations, IKE depletes intracellular glutathione (GSH) and triggers lipid peroxidation, culminating in iron-dependent programmed cell death (ferroptosis). Recent preclinical studies have highlighted its therapeutic potential across diverse pathological contexts, including hematological malignancies such as diffuse large B-cell lymphoma (DLBCL) and autoimmune conditions characterized by aberrant cellular proliferation. Notably, in the context of fibrotic and tissue-remodeling diseases, IKE has demonstrated the ability to eliminate pathogenic fibroblast-like cells, thereby reducing inflammation and tissue damage. However, because ferroptosis can also drive fibrotic damage in certain organs (such as the kidneys in systemic lupus erythematosus), the application of IKE requires precise, tissue-targeted delivery systems, such as PEG-PLGA nanoparticles, to maximize efficacy while minimizing adverse effects. Further clinical trials are essential to validate its safety, efficacy, and optimal combination therapies.
1. Introduction
Ferroptosis is a unique, iron-dependent form of regulated cell death driven by unchecked lipid peroxidation and the accumulation of lethal lipid reactive oxygen species (ROS) [1][2]. The induction of ferroptosis has emerged as a promising therapeutic strategy for diseases characterized by abnormal cell proliferation, including cancers and certain autoimmune disorders. Imidazole Ketone Erastin (IKE) has been developed as an advanced, highly potent ferroptosis inducer [1]. While initially explored for its anti-tumor properties in malignancies like diffuse large B-cell lymphoma (DLBCL), IKE is increasingly being investigated for its capacity to modulate immune responses and eliminate hyperactive fibroblasts, making it a compound of significant interest in the study of fibrotic and autoimmune diseases [1][2].
2. Pharmacological Activity
IKE exhibits robust pharmacological activity in both oncological and autoimmune/fibrotic preclinical models. In oncology, IKE has been shown to significantly inhibit tumor cell growth in mouse DLBCL xenograft models [1]. Its anti-tumor efficacy can be further amplified when used in combination therapies; for instance, combining IKE with zotatifin (a protein synthesis inhibitor) enhances the sensitivity of DLBCL cells to ferroptosis [1]. To improve its therapeutic window and delivery, researchers have successfully utilized PEG-PLGA nanoparticles as carriers for IKE in DLBCL treatment [1].
In the context of fibrotic and autoimmune diseases, IKE demonstrates targeted anti-fibroblast activity. In rheumatoid arthritis (RA), a chronic inflammatory disease driven by the abnormal proliferation of fibroblast-like synoviocytes (FLS), the administration of IKE effectively induces ferroptosis in these cells. In collagen-induced arthritis mouse models, IKE successfully reduced the number of fibroblasts in the synovium, which consequently alleviated inflammation and prevented further tissue damage [2]. This ability to selectively clear pathogenic fibroblasts highlights IKE's potential as a therapeutic agent for diseases driven by aberrant fibrotic tissue remodeling.
3. Molecular Mechanism of Action
The primary molecular mechanism of IKE involves the potent inhibition of system Xc-, a cystine/glutamate antiporter located on the plasma membrane [1]. By blocking the cellular uptake of cystine, IKE prevents its intracellular reduction to cysteine, which is the rate-limiting substrate for the biosynthesis of glutathione (GSH) [1][2]. The subsequent depletion of GSH directly impairs the activity of glutathione peroxidase 4 (GPX4), a critical antioxidant enzyme that normally neutralizes lipid hydroperoxides [1]. Without functional GPX4, IKE induces profound lipidomic changes through non-Fenton reaction-mediated lipid peroxidation, leading to the catastrophic accumulation of lipid ROS and the execution of ferroptotic cell death [1].
4. Structure-Activity Relationship (SAR)
IKE was designed as an improved structural analogue of the classical ferroptosis inducer, erastin [1]. The incorporation of a ketone moiety and an imidazole ring into the erastin scaffold significantly enhances its pharmacological profile. Consequently, IKE is more than 100 times more potent than its parent compound, erastin, allowing it to effectively inhibit system Xc- at substantially lower concentrations [1].
5. Current Limitations
Despite its promising preclinical profile, the clinical translation of IKE faces several limitations. First, its efficacy and safety profile have yet to be rigorously validated in human clinical trials [1]. Second, the systemic induction of ferroptosis presents a double-edged sword due to disease-specific mechanistic heterogeneity. While inducing ferroptosis with IKE is beneficial for eliminating hyperproliferative fibroblasts in RA or tumor cells in DLBCL, ferroptosis is highly pathogenic in other contexts. For example, in systemic lupus erythematosus (SLE), excessive ROS and ferroptosis in renal tubular epithelial cells exacerbate inflammation and fibrosis, leading to severe kidney damage (lupus nephritis) [2]. Therefore, the lack of inherent tissue selectivity means that systemic administration of IKE could inadvertently trigger fibrotic damage in vulnerable organs.
6. Future Perspectives
Future research on IKE must prioritize the development of precision-targeted delivery strategies to overcome its current limitations. The successful use of PEG-PLGA nanoparticles in preclinical models provides a strong foundation for designing tissue-specific modulators that can deliver IKE directly to tumors or hyperactive fibrotic tissues while sparing healthy organs [1][2]. Additionally, exploring combination therapies—such as pairing IKE with epigenetic modifiers, protein synthesis inhibitors, or other targeted biologics—will be crucial for maximizing its therapeutic window [1]. Ultimately, rigorous clinical trials and the integration of spatial transcriptomics and AI-driven drug design will be necessary to transition IKE from a preclinical tool into a viable, precision-targeted therapeutic paradigm for fibrotic diseases and malignancies [1][2].
